• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本中央骨髓数据中心报告。

Report of the Japanese Central Bone Marrow Data Center.

作者信息

Tanaka H, Akaza T, Juji T

机构信息

Japanese Red Cross Central Blood Center, Tokyo, Japan.

出版信息

Clin Transpl. 1996:139-44.

PMID:9286563
Abstract

The Japan Marrow Donor Program started to recruit donors at the beginning of 1992 with the financial support of the Japanese government, and the first unrelated bone marrow transplantation arranged through this program was performed in 1993. Since 1992, about 82,000 donors and 4,400 patients have been registered. At least one HLA-identical donor has been found for 60% of the patients in the first search after the patients register with the JMDP, and as of the end of September 1996, 880 patients had received bone marrow transplants from unrelated donors. The results of 19.7% of registered patients having received bone marrow transplants and 1.1% of registered donors having donated far exceed our forecasts. This is attributed to the high frequency of several haplotypes in the Japanese. However, no HLA-identical donors have been found for approximately 800 registered patients so far. Thus, it is still necessary to increase the number of donors registered with the JMDP.

摘要

日本骨髓捐赠项目于1992年初在日本政府的财政支持下开始招募捐赠者,通过该项目安排的首例非亲属骨髓移植于1993年进行。自1992年以来,约有82000名捐赠者和4400名患者进行了登记。在患者向日本骨髓捐赠项目登记后的首次搜索中,60%的患者至少找到了一名HLA匹配的捐赠者,截至1996年9月底,880名患者接受了非亲属捐赠者的骨髓移植。19.7%的登记患者接受了骨髓移植,1.1%的登记捐赠者进行了捐赠,这一结果远远超出了我们的预期。这归因于日本人中几种单倍型的高频率。然而,到目前为止,约800名登记患者尚未找到HLA匹配的捐赠者。因此,仍有必要增加在日本骨髓捐赠项目登记的捐赠者数量。

相似文献

1
Report of the Japanese Central Bone Marrow Data Center.日本中央骨髓数据中心报告。
Clin Transpl. 1996:139-44.
2
Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients.寻找非亲属骨髓供者的问题及可能的解决方法。240例荷兰患者连续搜索的结果。
Bone Marrow Transplant. 1997 Dec;20(12):1011-7. doi: 10.1038/sj.bmt.1701025.
3
Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program.非亲缘供者骨髓移植:国家骨髓供者计划的经验
Clin Transpl. 1994:295-301.
4
[Search for bone marrow donors for patients with hematologic-oncologic diseases].
Beitr Infusionsther. 1990;26:214-6.
5
[HLA typing in the Japanese Bone Marrow Program].
Rinsho Byori. 1997 Feb;45(2):157-60.
6
Computer program to predict likelihood of finding and HLA-matched donor: methodology, validation, and application.预测找到 HLA 匹配供体可能性的计算机程序:方法、验证及应用
Biol Blood Marrow Transplant. 1996 Oct;2(3):134-44.
7
Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program.非血缘供者骨髓移植:国家骨髓捐献项目的经验
Clin Transpl. 1995:271-7.
8
Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO).儿童无关供者骨髓移植:来自意大利儿科血液学和肿瘤学协会(AIEOP)及意大利骨髓移植小组(GITMO)的报告
Haematologica. 2002 Aug;87(8 Suppl):51-7.
9
[Genetic analysis of Italian hematologic patients candidates for bone marrow transplantation from unrelated donors].[意大利等待非血缘供者骨髓移植的血液病患者的基因分析]
Ann Ist Super Sanita. 1999;35(1):35-40.
10
Feasibility of finding an unrelated bone marrow donor on international registries for New Zealand patients.新西兰患者在国际骨髓捐献者登记处寻找非亲属骨髓捐献者的可行性。
Bone Marrow Transplant. 1999 Feb;23(3):291-4. doi: 10.1038/sj.bmt.1701561.

引用本文的文献

1
Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn's Disease: A Case Report and Review of the Literature.乌司奴单抗治疗克罗恩病相关性脊柱关节炎的疗效:病例报告及文献综述
Open Access Rheumatol. 2020 Jul 29;12:133-137. doi: 10.2147/OARRR.S263259. eCollection 2020.
2
Stress fracture of the midshaft clavicle associated with sternocostoclavicular hyperostosis-Case report.与胸锁关节骨质增生相关的锁骨中段应力性骨折——病例报告
Int J Surg Case Rep. 2019;58:121-126. doi: 10.1016/j.ijscr.2019.03.059. Epub 2019 Apr 19.
3
Characteristics of late-onset spondyloarthritis in Japan: A retrospective cohort study.
日本迟发性脊柱关节炎的特征:一项回顾性队列研究。
Medicine (Baltimore). 2019 Feb;98(7):e14431. doi: 10.1097/MD.0000000000014431.
4
Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases.人类白细胞抗原(HLA)在自身免疫性疾病中的作用。
Rheumatol Ther. 2018 Jun;5(1):5-20. doi: 10.1007/s40744-018-0100-z. Epub 2018 Mar 7.
5
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.在病毒学抑制的人类免疫缺陷病毒感染患者中,从抗逆转录病毒药物替诺福韦酯/恩曲他滨转换为硫酸阿巴卡韦/拉米夫定后脂质浓度的评估。
Intern Med. 2016;55(23):3435-3440. doi: 10.2169/internalmedicine.55.7518. Epub 2016 Dec 1.
6
Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.HLA - B*58:01等位基因与别嘌醇诱导的皮肤药物不良反应的影响:来自21项药物遗传学研究的证据
Oncotarget. 2016 Dec 6;7(49):81870-81879. doi: 10.18632/oncotarget.13250.
7
Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.在未经治疗的日本个体中,Gag蛋白酶介导的HIV-1复制能力对临床参数缺乏显著影响。
Retrovirology. 2015 Nov 19;12:98. doi: 10.1186/s12977-015-0223-z.
8
Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab.日本轴向型脊柱关节炎患者的临床特征及阿达木单抗的短期疗效。
J Orthop Sci. 2015 Nov;20(6):1070-7. doi: 10.1007/s00776-015-0755-z. Epub 2015 Aug 6.
9
Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan.日本上市后监测中Epzicom®(拉米夫定/硫酸阿巴卡韦)的安全性分析。
Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):372-81. doi: 10.1002/pds.3588. Epub 2014 Mar 3.
10
Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan.日本上市后监测中佳息患®(硫酸阿巴卡韦)的安全性分析。
Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):361-71. doi: 10.1002/pds.3589. Epub 2014 Mar 3.